FFM
IKT icon

Fairmount Funds Management’s Inhibikase Therapeutics IKT Stock Holding History

Fairmount Funds Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.5M Hold
8,625,000
– – 1.05% 12
2025
Q4 		$17.7M Buy
8,625,000
+2,500,000
+41% +$3.98M 1.35% 13
2025
Q3 		$9.92M Hold
6,125,000
– – 0.89% 17
2025
Q2 		$11.9M Hold
6,125,000
– – 1.55% 16
2025
Q1 		$13.4M Hold
6,125,000
– – 2.08% 14
2024
Q4 		$19.9M Buy
+6,125,000
New +$15.3M 1.98% 16

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Fairmount Funds Management's IKT Position: Q1 2026 in Review

Fairmount Funds Management held its Inhibikase Therapeutics (IKT) position steady in Q1 2026 at 8,625,000 shares worth $14.5M. The position accounts for 1.05% of the portfolio, ranked #12.

Fairmount Funds Management first reported a position in IKT in Q4 2024 and has held it in 6 quarters since. The position peaked at $19.9M in Q4 2024. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Fairmount Funds Management held 8,625,000 shares of Inhibikase Therapeutics worth $14.5M as of Q1 2026.
  • Fairmount Funds Management left its Inhibikase Therapeutics share count unchanged in Q1 2026.
  • Inhibikase Therapeutics made up 1.05% of Fairmount Funds Management's portfolio in Q1 2026, its #12 holding.
  • Fairmount Funds Management first reported a position in Inhibikase Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Fairmount Funds Management's Inhibikase Therapeutics position peaked at $19.9M in Q4 2024.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Fairmount Funds Management's 13F filing for Q1 2026, filed 15 May 2026.